MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

MDT

89.97

+0.71%↑

VEEV

275.84

-1.9%↓

A

123.3

-0.67%↓

WBA

11.51

-0.35%↓

HQY

94.45

-2.78%↓

Search

CytomX Therapeutics Inc

Chiusa

SettoreSettore sanitario

2.41 -7.66

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.4

Massimo

2.44

Metriche Chiave

By Trading Economics

Entrata

4.6M

24M

Vendite

13M

51M

P/E

Media del settore

4.938

39.564

Margine di Profitto

46.203

Dipendenti

119

EBITDA

4.9M

23M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+65.29% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

202M

373M

Apertura precedente

10.07

Chiusura precedente

2.41

Notizie sul Sentiment di mercato

By Acuity

50%

50%

131 / 376 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

CytomX Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 lug 2025, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

FCC Approves U.S. Cellular Sale to T-Mobile

11 lug 2025, 17:28 UTC

I principali Market Mover

SharpLink Gaming Gains on Ethereum Purchase

11 lug 2025, 16:57 UTC

Utili

BASF Cuts Outlook on Global Economy Uncertainty

12 lug 2025, 02:24 UTC

Acquisizioni, Fusioni, Takeovers

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- Update

12 lug 2025, 02:05 UTC

Acquisizioni, Fusioni, Takeovers

Google to Pay $2.4 Billion in Deal to License Tech of Coding Startup, Hire CEO -- WSJ

12 lug 2025, 02:05 UTC

Acquisizioni, Fusioni, Takeovers

Google to Hire Windsurf CEO and Other Employees, Company Says -- WSJ

12 lug 2025, 02:05 UTC

Acquisizioni, Fusioni, Takeovers

Google to Pay About $2.4 Billion in Deal to License Tech of AI Coding Startup, Sources Say -- WSJ

11 lug 2025, 21:45 UTC

Discorsi di Mercato

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 lug 2025, 19:46 UTC

Acquisizioni, Fusioni, Takeovers

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 lug 2025, 19:45 UTC

Discorsi di Mercato

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 lug 2025, 19:05 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 lug 2025, 18:18 UTC

Discorsi di Mercato

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 lug 2025, 17:35 UTC

Discorsi di Mercato

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 lug 2025, 17:26 UTC

Discorsi di Mercato

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 lug 2025, 16:53 UTC

Discorsi di Mercato

Crude Futures Add to Early Gains -- Market Talk

11 lug 2025, 16:42 UTC

Utili

BASF Cuts Outlook on Global Economic Uncertainty

11 lug 2025, 16:08 UTC

Discorsi di Mercato

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 lug 2025, 16:05 UTC

Utili

BASF Will Publish Half-Year Results on July 30

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

11 lug 2025, 16:04 UTC

Discorsi di Mercato

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 lug 2025, 16:03 UTC

Utili

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 lug 2025, 16:02 UTC

Utili

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 lug 2025, 16:01 UTC

Utili

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 lug 2025, 16:00 UTC

Utili

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 lug 2025, 15:59 UTC

Utili

BASF Cuts 2025 Earnings View

11 lug 2025, 15:58 UTC

Utili

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 lug 2025, 15:57 UTC

Utili

BASF 2Q EBIT Before Special Items EUR810M

11 lug 2025, 15:54 UTC

Utili

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 lug 2025, 15:54 UTC

Utili

BASF 2Q Sales Fell 2.1% on Year

11 lug 2025, 15:53 UTC

Utili

BASF 2Q Sales EUR15.77B

Confronto tra pari

Modifica del prezzo

CytomX Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

65.29% in crescita

Previsioni per 12 mesi

Media 4 USD  65.29%

Alto 5 USD

Basso 2.5 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per CytomX Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

3

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

0.7658 / N/ASupporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Very Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Sentiment

By Acuity

131 / 376 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo CytomX Therapeutics Inc

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.